0.6368  0.025 (4%)		10-24 15:02
Open: 0.6078 High: 0.6689 Volume: 279,628		Pre. Close: 0.6123 Low: 0.6078 Market Cap: 2(M)

Short term
Mid term
Targets	6-month :	0.93	1-year :	1.1
Resists	First :	0.8	Second :	0.94
Pivot price	0.7
Supports	First :	0.56	Second :	0.46
MAs	MA(5) :	0.66	MA(20) :	0.69
	MA(100) :	1.05	MA(250) :	21.94
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	14.6	D(3) :	17
RSI	RSI(14): 42.4
52-week	High :	123.75	Low :	0.56

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ENVB ] has closed above bottom band by 27.8%. Bollinger Bands are 8.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.63 - 0.64	0.64 - 0.64
Low:	0.56 - 0.57	0.57 - 0.57
Close:	0.6 - 0.62	0.62 - 0.62

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Thu, 23 Oct 2025
Enveric Biosciences Announces Reverse Stock Split - Business Wire

Wed, 15 Oct 2025
Enveric Biosciences (ENVB) Pursues Legal Action Against AbbVie - GuruFocus

Wed, 15 Oct 2025
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal - Investing News Network

Thu, 02 Oct 2025
Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials - Investing News Network

Thu, 02 Oct 2025
Enveric Biosciences (ENVB) Advances Development of Lead Candidat - GuruFocus

Thu, 02 Oct 2025
Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	6 (M)
Shares Float	3 (M)
Held by Insiders	6.8 (%)
Held by Institutions	13.2 (%)
Shares Short	309 (K)
Shares Short P.Month	398 (K)

EPS	-9.98
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.72
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-129.8 %
Return on Equity (ttm)	-262 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.56
Qtrly Earnings Growth	0 %
Operating Cash Flow	-7 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-0.07
PEG Ratio	0
Price to Book value	0.88
Price to Sales	0
Price to Cash Flow	-0.62

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.